Avexitide Hits Phase 3 Primary Endpoint with 55% Reduction in Hypoglycemic Events
AMLX has more than doubled off its 52-week low of $7.63.
Summary
Amylyx's avexitide met the primary endpoint in the Phase 3 LUCIDITY trial, showing a 55% reduction in Level 2 and Level 3 hypoglycemic events versus placebo (p=0.000003) in post-bariatric hypoglycemia patients. All secondary endpoints were also met with high statistical significance. The company plans to submit an NDA by end of 2026, with potential commercial launch in 2027 if approved. This is the first positive Phase 3 data for a potential first-in-class treatment for PBH, a condition with no approved therapies. The stock is trading near its 52-week high, and this result could significantly de-risk the regulatory path. Watch for the NDA submission and FDA acceptance timeline.
At the time of this announcement, AMLX was trading at $26.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $7.63 to $24.60. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: BusinessWire.